5th AROME – MONTENEGRO COURSE

Iberostar hotel Montenegro, Bečići, Budva, MontenegroOctober, 7 – 9, 2021

5th AROME – MONTENEGRO COURSEBridge between Science and Clinics in Oncology

4th AROME ESO Joint Consensus Conference

Association ofRadiotherapy and Oncologyof the Mediterranean Area

ZAPOČNITE SADADA PRODUŽITEPREŽIVLJAVANJE1,2,3,4

NEXAVAR® (sorafenib)

NAZIV LIJEKA: Nexavar®, sorafenib, 200 mg, film tableteNOSILAC DOZVOLE: Evropa Lek Pharma d.o.o., Telefon: +382 (0) 77 272 735, Kritskog odreda 4/1, 81000 Podgorica, Crna Gora, BROJ DOZVOLE ZA STAVLJANJE LIJEKA U PROMET: 2030/10/2 - 3246 DATUM PRVE DOZVOLE/OBNOVE DOZVOLE ZA STAVLJANJE LIJEKA U PROMET: 26.02.2010.

PP

-NE

X-M

E-0

008-

1

Za odgovarajuće pacijente sa inoperabilnim hepatocelularnim karcinomom

Reference:1. Llovet JM, Ricci S, Mazzaferro V, et al; for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390;2. Cheng AL, Kang ZK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34;3. Bruix J, Qin S, Merle P, et al; on behalf of the RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebocontrolled, phase 3 trial [published online December 5, 2016]. Lancet. 2016. doi: 10.1016/S0140-6736(16)32453-9; 5. STIVARGA (regorafenib) sažetak opisa svojstava lijeka 09/2019.4. Nexavar®, 200 mg, film tablete, Sažetak karakteristika lijeka, septembar 2020.

Samo za stručnu javnost.




PP

-NE

X-M

E-0

008-

1







PP

-NE

X-M

E-0

008-

1




7th to 9th October 2021, Budva, Montenegro

5th AROME – MONTENEGRO COURSEBridge between Science and Clinics in Oncology

4th AROME ESO Joint Consensus Conference

PRESIDENCY:

Vladimir TODOROVIC (Meeting President)Institute for Oncology, Clinical Center of Montenegro, University of Montenegro,

Podgorica, Montenegro

Joseph GLIGOROV (AROME former President)Institut Universitaire de Cancérologie APHP-Sorbonne Université, Paris, France

Matti AAPRO (ESO executive board member)Clinique du Génolier, Génolier, Switzerland

SCIENTIFIC COMMITTEE:

M Aapro (Switzerland), Y Belkacemi (France), J Gligorov (France), N Pavlidis (Greece), V. Todorovic (Montenegro), P Tsoutsou (Greece).

FACULTY:

M Aapro (Switzerland), O Arsovski (Bosna & Hercegovina), Y Belkacemi (France), A Benider (Morocco), S Beslija (Bosnia & Hercegovina), A Bounedjar (Algeria), H.

Boussen (Tunisia), T Ceric (Bosnia & Hercegovina), N Crnogorac (Montenegro), N Dedic-Plavetic (Croatia), I Djan (Serbia), Z Dzamic (Serbia), A Eniu (Romania), H

Errihani (Morocco), F Geara (Lebanon), J Gligorov (France), Z Gojkovic (Bosnia & Hercegovina), A Id Baih (France), A Janjic (Serbia), R Jankovic (Serbia), K Kerrou

(France), V Kovcin (Serbia), J Lakicevic (Montenegro), I Markovic (Serbia), N Mijalkovic (Serbia), M Moran (USA), N Milasevic (Montenegro), K Mokhtari (France),

G Mustacchi (Italy), M Ozsahin (Switzerland), A Pasic (Bosnia & Herzegovina), N Pavlidis (Greece), L Popovic (Serbia), D Radosavljevic (Serbia), N Radosevic

(France), S Radulovic (Serbia), M Risteski (North Macedonia), Lj Stamatovic (Serbia), T Stantic (Serbia), S Stojanovic (Serbia), I Stojkovski (North Macedonia), I Takac

(Slovenia), V Todorovic (Montenegro), Z Tomasevic (Serbia), Z Tomasevic (Serbia), P Tsoutsou (Switzerland), S Turkan (Turkey), N Vasev (North Macedonia), D Vrbanec

(Croatia), F Vukmirovic (Montenegro) M Zdralevic (Montenegro).

MEETING ORGANIZATION AND REGISTRATION CONTACT:

Novi ASTAKOS Travel & Events e-mail: [email protected] www.astakos.com/arome

THURSDAY 7th OCTOBER 2021

Opening session – Hall A

13.00–14.15 Registration and welcome coffee

14.15–14.30 AROME-ESO course, past, present and future Vladimir Todorovic & Joseph Gligorov

14.30–15.00 COVID-19 & cancer care challenges in emerging countries Yazid Belkacemi (France)

Session 1: Innovations in diagnostics and locoregional treatments – Hall A

chairs: Sinisa Radulovic (Serbia), Damir Vrbanec (Croatia)

15.00–15.15 Molecular biology Masa Zdralevic (Montenegro)

15.15–15.30 PET-CT Khaldoun Kerrou (France)

15.30–15.45 Surgery Ivan Markovic (Serbia)

15.30–15.45 Radiotherapy Mahmut Ozsahin (Switzerland)

Session 2: Organization challenges in emerging countries – Hall Achairs: Nebojsa Crnogorac (Montenegro), Adda Bounedjar (Algeria)

15.45–16.00 Fertility preservation Natalija Dedic-Plavetic (Croatia)

16.00–16.15 Interventional radiology Sanja Stojanovic (Serbia)

16.15–16.30 Supportive and palliative care Jadranka Lakicevic (Montenegro)

16.30–16.45 Private Oncology Practice Vladimir Kovcin (Serbia)

16.45–17.15 General Discussion sessions 1 & 2

17.30–19.30 Industry sponsored educational programs – Hall A BRISTOL MYERS SQUIBB

The past, present and future of Immuno-Oncology – Vladimir Todorovic Long-term survival data with dual I-O approach in metastatic

melanoma – Janja Ocvirk

Utilizing I-O Approach in aRCC – Lazar Popovic

Immune Checkpoint Inhibitors – New era in the mesothelioma treatment landscape – Marko Jakopovic

Long term survival benefit of dual checkpoint inhibitor combination in NSCLC – Miroslav Samarzija

Q&A and discussion

17.30–18.15 Industry sponsored educational programs – Hall B MERCK

mCRC debate: Erbitux 1L & 3L mCRC- new concept of treatment RAS wt patients – Ivan Nikolic, Nenad Mijalkovic, Sanja Lekic

18.15–19.00 Industry sponsored educational programs – Hall B NOVARTIS

The importance of targeted therapy in the early treatment of BRAF mutated melanoma – Nikola Milašević, Nada Cicmil Sarić i Luka Simetić

FRIDAY 8th OCTOBER 2021

Session 3: Breast cancers treatments innovations – Hall Achairs: Giorgio Mustacchi (Italy), Nino Vasev (North Macedonia)

08.30–08.45 Pathological & Molecular diagnosis Nina Radosevic (France)

08.45–09.00 New radiotherapy standards and options Fady Geara (Lebanon)

09.00–09.15 anti-HER2 treatments Semir Beslija (Bosna & Hercegovina)

09.15–09.30 Endocrine treatments Hamouda Boussen (Tunisia)

09.30–09.45 Targeted treatments for TNBC Hassane Errihani (Morocco)

09.45–10.15 Coffee break

Session 4: Gynecologic cancers treatments innovations – Hall Achairs: Zdenka Gojkovic (Bosnia & Hercegovina), Zorica Tomaševic (Serbia)

10.15–10.30 Surgery Iztok Takac (Slovenia)

10.30–10.45 Radiotherapy Oliver Arsovski (Bosna & Hercegovina)

10.45–11.00 Systemic treatments Ljiljana Stamatovic (Serbia)

11.00–11.15 General Discussion sessions 3 & 4

11.15–12.00 Industry sponsored educational programs Hall A ROCHE

Imagine flexible health care system

moderator: Jadranka Lakićević

11.15–11.25 What is flexible healthcare? – Nada Cicmil Sarić

11.25–11.30 Patient preference for treatment decentralization in HER2 positive BC in MNE – Jadranka Lakićević

11.30–11.45 Clinical evidence and value of SC formulation of dual HER2 blockade – Ljiljana Stamatović

11.45–11.55 Real world evidence – decentralization advantages – Evandro de Azambuja – Stephanie Hecther

11.55–12.00 Conclusion – Jadranka Lakićević

11.15–12.00 Industry sponsored educational programs Hall B PFIZER

mRCC treatment in new decade – Milan Sorat

How to navigate towards all new options? What is the best sequence in a multi-line setting? – Nikola Milašević

Optimizing systemic therapy in advanced RCC; What does current practice look in Montenegro? – Nevenka Lukovac Janjić

12.00–12.45 Industry sponsored educational programs Hall A MSD / Glosarij CD

„Pembrolizumab – a Key for better outcomes in NSCLC treatment“. Timur Cerić, moderator, Marija Stolić, Ana Delić Vukićević

12.00–12.45 Industry sponsored educational programs Hall B AMICUS – Vectibix

Treatment of Colorectal Carcinoma – Where do we stand? – Davorin Radosavljević

Vectibix in 1st line mCRC treatment – Ivan Nikolić

Vectibix monotherapy in the treatment of mCRC – Nikola Milašević

Sharing experience from Bosnia and Herzegovina – case report – Anes Pašić

12.45–14.00 Lunch

Session 5: Head & Neck and Cutaneous cancers treatments innovations – Hall A

chairs: Sedat Turkan (Turkey), Vladimir Kovcin (Serbia)

14.00–14.15 Head & Neck Igor Djan (Serbia)

14.15–14.30 Melanoma Nikola Milasevic (Montenegro)

14.30–14.45 Non melanoma cutaneous cancers Igor Stojkovski (N. Macedonia)

Session 6: Gastro Intestinal cancers treatments innovations – Hall A

Chairs: Abdellatif Benider (Morocco), Igor Stojkovski (North Macedonia)

14.45–15.00 Pathological & Molecular diagnosis Filip Vukmirovic (Montenegro)

15.00–15.15 Colorectal Anes Pasic (Bosnia & Hercegovina)

15.15–15.30 Non-Colorectal Nenad Mijalkovic (Serbia)

15.30–16.00 General Discussion session 5 & 6

16.00–16.30 Coffee Break

Session 7: Urologic cancers treatments innovations – Hall A

chairs: Lazar Popovic (Serbia), Zoran Dzamic (Serbia)

16.30–16.45 Challenges in early diagnosis Tomislav Stantic (Serbia)

16.45–17.00 Prostate Aleksandar Janjic (Serbia)

17.00–17.15 Urothelial & Renal cell Milan Risteski (North Macedonia)

Session 8: Lung cancers treatments innovations – Hall A

chairs: Paula Tsoutsou (Greece), Zoran Tomasevic (Serbia)

17.15–17.30 Molecular diagnosis Radmila Jankovic (Serbia)

17.30–17.45 Immune-checkpoint treatments Timur Ceric (Bosnia & Hercegovina)

17.45–18.00 Targeted therapies Davorin Radosavljevic (Serbia)

18.00–18.30 Discussion session 7 & 8

18.30–19.00 Primary CNS malignant tumors Karima Mokhtari & Ahmed Id Baih (France)

19.00–20.00 Education sponsored session – Hall A ROCHE

Fusing data with experience in hepatocellular carcinoma

Moderator: Vladimir Todorović

19.00–19.05 Unprecedented unmet need – Vladimir Todorović

19.05–19.20 Brave achievement with IMbrave150 – Davorin Radosavljević

19.20–19.30 Whats the latest advice? – Nenad Mijalković

By putting lives first, we’ve created a legacy that lastsFor 130 years, we have tackled some of the world’s biggest health challenges and provided hope in the fight against disease, for both people and animals. Today, we continue our commitment to be the premier research-intensive biopharmaceutical company in pursuit of medical breakthroughs that benefit patients and society for today, tomorrow and generations to come.

Copyright © 2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. ME-KEY-00036

Glosarij d.o.o.Vojislavljevića 76, 81 000 Podgorica,Crna Gora

19.30–19.55 Futures promise: MDT dialogue – Petar Popovič, Gašper Boltežar

19.55–20.00 Conclusion – Vladimir Todorović

19.00–20.00 Education sponsored session – Hall B PFIZER

Treatment guidelines for hormone positive breast cancer – Nada Cicmil

Endocrine therapy for metastatic breast cancer in COVID 19 era (treatment priorities) – Jadranka Lakicević

Palbociclib – from clinical trials to clinical practice – RWD Oncology Institute, Clinical Center of Montenegro – Sanja Lekić

21.00 Gala Dinner SPONSORED BY MSD / GLOSARIJ CD

SATURDAY 9TH OCTOBER 2021

Special Educational Lectures of challenges in emerging countries – Hall A

Chairs: Yazid Belkacemi (France), Paula Tsoutsou (Greece)

09.00–09.30 Challenges on cancer education in emerging countries: ESO experience Alexander Eniu (Romania)

09.30–09.50 Recent advances on CUP Nicolaos Pavlidis (Greece)

09.50–10.30 Coffee Break

AROME-ESO JOINT CONSENSUS CONFERENCE – HALL A

Prioritizing Strategies for Access to Cancer Care and Innovations in Emerging Countries

Joseph Gligorov (France), Vladimir Todorovic (Montenegro), Matti Aapro (Switzerland), Nicolaos Pavlidis (Greece)

10.30–12.30 Expert discussion and voting session

12.30–12.45 Closing remarks

Who we are. What we do. Why we come to work each day?

We believe it’s urgent to deliver medical solutions right now – even as we develop innovationsfor the future. That is why we come to work each day. We commit ourselves to scientific rigor,unassailable ethics, and access to medical innovations for all.

We have been committed to improving lives since the company was founded in 1896 in Basel,Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millionsof patients globally.

We are the world’s number 1 in biotech with 17 biopharmaceuticals on the market. Over half ofthe compounds in our product pipeline are biopharmaceuticals, enabling us to deliver better-targeted therapies.

We are global leader in cancer treatments. We have been at the forefront of cancer researchand treatment for over 50 years, with medicines for breast, skin, colon, ovarian, lung and numerousother cancers.

We invest around 9 billion Swiss francs in Research and Development every year becauseinnovation is our lifeblood. This is amongst the highest Research and Development spends inthe world across all industries.

We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world.

Roche celebrate life:125 years of recognizing life as the most precious gift

On 1 October 2021, Roche turns 125 years old!

There seems to be an inherent human desire to push the boundaries of life. In the space of only125 years, the average life expectancy has more than doubled. This was only possible throughthe deliberate nurturing of scientific curiosity and innovation.

But it’s not about the numbers. It’s an investment in moments.

More days, months, years of life. More moments to cherish. More hopes and dreams to inspirethe future. More reasons to celebrate. Because life, at its core, is about celebration – whethercreating new memories or savoring moments of our past. Who we are today at Roche is anaccumulation of millions of moments experienced by many thousands of individuals acrossseveral generations.

This has been the driving force behind our work for 125 years, and this is what will spark themoments of eureka that will propel science forward for the next 125.

We are Roche.

Doing now what patients need next

NOTES

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PLATINUM SPONSORS

SILVER SPONSOR

SPONSORS

5th AROME – MONTENEGRO COURSE

Documents

Transcript of 5th AROME – MONTENEGRO COURSE